{"id":"9f6d19416613","type":"article","url":"https://hartvaat.nl/2024/01/30/edoxaban-versus-warfarine-bij-chronische-trombo-embolische-pulmonale-hypertensie/","title":"Edoxaban versus warfarine bij chronische trombo-embolische pulmonale hypertensie","title_en":"A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.123.067528","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.123.067528","authors":["Kazuya Hosokawa","Hiroko Watanabe","Yu Taniguchi","Nobutaka Ikeda","Takumi Inami","Satoshi Yasuda","Toyoaki Murohara","Masaru Hatano","Yuichi Tamura","Jun Yamashita","Koichiro Tatsumi","Ichizo Tsujino","Yuko Kobayakawa","Shiro Adachi","Nobuhiro Yaoita","Shun Minatsuki","Koji Todaka","Keiichi Fukuda","Hiroyuki Tsutsui","Kohtaro Abe"],"significance":7,"published":"2024-01-30","source_date":"2024-01-30","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/hypertensie/thiazidediuretica-hypertensie/"],"congress":"","summary_en":"This randomized trial showed that edoxaban is noninferior to warfarin for preventing thromboembolic events in patients with chronic thromboembolic pulmonary hypertension, providing a DOAC option for anticoagulation in this pulmonary vascular disease.","created":"2026-07-03T10:30:45Z","updated":"2026-07-03T13:29:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Gerandomiseerde trial vergeleek edoxaban met warfarine bij CTEPH. Edoxaban was non-inferieur wat betreft trombotische events en gaf minder bloedingen. NOAC-gebruik bij CTEPH is veilig en effectief als alternatief voor VKA.","abstract_original":""}